Effects of eryrthropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells

American Journal of Hypertension

Volumn 10, Issue 3, 1997, Pages 289-296

  Vogel, Volker ^a,b   Kramer, Herbert J ^a,b   Bäcker, Angela ^a,b   Meyer Lehnert, Harald ^a,b   Jelkmann, Wolfgang ^a,b   Fandrey, Joachim ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

calcium; endothelin 1; endothelium; erythropoietin; hypertension; renal anemia; tyrosine kinase

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 3,4,5 TRIMETHOXYBENZOIC ACID 8 (DIETHYLAMINO)OCTYL ESTER; CALCIMYCIN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; ERYTHROPOIETIN; GENISTEIN; NICKEL; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RECOMBINANT ERYTHROPOIETIN; VERAPAMIL; CALCIUM; DRUG DERIVATIVE; ENZYME INHIBITOR; GALLIC ACID; IONOPHORE; ISOFLAVONE DERIVATIVE; PROTEIN KINASE C;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SWINE; SYNTHESIS; VASCULAR ENDOTHELIUM; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SECOND MESSENGER; VASCULAR SMOOTH MUSCLE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CALCIMYCIN; CALCIUM; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; ERYTHROPOIETIN, RECOMBINANT; GALLIC ACID; GENISTEIN; IONOPHORES; ISOFLAVONES; MUSCLE, SMOOTH, VASCULAR; PROTEIN KINASE C; RECEPTOR PROTEIN-TYROSINE KINASES; SECOND MESSENGER SYSTEMS; SWINE; VERAPAMIL;

EID: 0030614967     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00410-4     Document Type: Article

References (29)

1. Eschbach JW, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicentre clinical trial. Ann Intern Med. 111:1989;992-1000.
2. Akizawa T, Koshikawa S, Takaku F, et al. Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure. A multiinstitutional study in Japan. Int J Artif Organs. 11:1988;343-350.
3. Samtleben W, Baldamus CA, Bommer J, et al. Blood pressure changes during therapy with recombinant erythropoietin. Contrib Nephrol. 66:1988;114-122.
4. Raine AEG. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet. 1988;97-99.
5. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
6. Bode-Böger SM, Böger RH, Kuhn M, et al. Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol. 20:((suppl 12):1992;25-28.
7. Carlini RG, Dusso AS, Obialo CI, et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 43:1993;1010-1014.
8. Carlini RG, Obialo CI, Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. J Hypertens. 6:1993;103-107.
9. Neusser M, Tepel M, Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res. 27:1993;1233-1236.
10. Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int. 39:1991;259-265.
11. 2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol. 24:1996;392-397.
12. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA. 91:1994;3974-3978.
13. Mladenovic J, Kay NE. Erythropoietin induces rapid increases in intracellular free calcium in human bone marrow cells. J Lab Clin Med. 112:1988;23-27.
14. Imagawa S, Smith BR, Palmer-Crocker R, Bunn HF. The effect of recombinant erythropoietin on intracellular free calcium in erythropoietin-responsive cells. Blood. 73:1989;1452-1457.
15. Miller BA, Cheung JY. Mechanisms of erythropoietin signal transduction: involvement of calcium channels. Proc Soc Exp Biol Med. 206:1994;263-267.
16. Yanagisawa M, Inoue A, Takuwa Y, et al. The human preproendothelin-1 gene: possible regulation by endothelial phosphoinositide turnover signaling. J Cardiovasc Pharmacol. 13:((suppl 5)):1989;13-17.
17. Lüscher TF, Oemar B, Boulanger CM, Hahn AWA. Molecular and cellular biology of endothelin and its receptors - Part 1. J Hypertens. 11:1993;7-11.
18. Migas I, Bäcker A, Meyer-Lehnert H, Kramer HJ. Endothelin synthesis by porcine inner medullary collecting duct cells: effects of hormonal and osmotic stimuli. 8:1995;748-752.
19. Safar ME, London GM. Venous system in essential hypertension. Clin Sci. 69:1985;497-504.
20. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. J Clin Invest. 52:1973;2745-2756.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem. 193:1951;265-275.
22. Hassid A, Pidikiti N, Gamero D. Effects of vasoactive peptides on cytosolic calcium in cultured mesangial cells. Am J Physiol. 251:1986;1018-1028.
23. Grynkiewicz G, Poenie M, Tsien RY. A new generation of calcium indicators with greatly improved fluorescence properties. J Biol Chem. 260:1985;3440-3450.
24. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48:1988;4827-4833.
25. Misiti J, Spivak JL. Erythropoiesis in vitro: role of calcium. J Clin Invest. 64:1979;1573-1579.
26. Corder R, Khan N, Änggard EE, Vane JR. Calcium ionophores inhibit the release of endothelin-1 from endothelial cells. J Cardiovasc Pharmacol. 22:((suppl 8)):1993;42-45.
27. Mitchel MD, Branch DW, Lamarche S, Dudley DJ. The regulation of endothelin production in human umbilical vein endothelial cells: unique inhibitory action of calcium ionophores. J Clin Endocrinol Metab. 75:1992;665-668.
28. Pfeilschifter J, Fandrey J, Ochsner M, et al. Potentiation of angiotensin II-stimulated phosphoinositide hydrolysis, calcium mobilization and contraction of renal mesangial cells upon down-regulation of protein kinase C. FEBS Lett. 261:((2)):1990;307-311.
29. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 74:1993;227-236.